An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell Transplantation
Latest Information Update: 02 Jan 2024
At a glance
- Drugs Emapalumab (Primary)
- Indications Transplant rejection
- Focus Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors Swedish Orphan Biovitrum
- 25 Jul 2022 Status changed from suspended to discontinued on sponsor decision related to business priorities, assessment of development options.
- 08 Mar 2022 Status changed from recruiting to suspended since new development plan is conducted.
- 03 May 2021 Status changed from not yet recruiting to recruiting.